 Christian Young
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 9 | 2023 | 610 | 2.100 |
Why?
| | Head and Neck Neoplasms | 7 | 2023 | 471 | 1.830 |
Why?
| | Phosphatidylinositol 3-Kinases | 9 | 2022 | 343 | 1.320 |
Why?
| | Receptor, ErbB-2 | 10 | 2017 | 320 | 1.250 |
Why?
| | Receptor, ErbB-3 | 7 | 2017 | 42 | 1.230 |
Why?
| | Breast Neoplasms | 12 | 2017 | 1965 | 1.190 |
Why?
| | Mouth Neoplasms | 3 | 2023 | 79 | 1.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 57 | 0.880 |
Why?
| | Mammary Glands, Animal | 5 | 2015 | 124 | 0.790 |
Why?
| | Mammary Neoplasms, Experimental | 4 | 2014 | 63 | 0.780 |
Why?
| | Cell Line, Tumor | 18 | 2022 | 2851 | 0.760 |
Why?
| | Precancerous Conditions | 1 | 2022 | 160 | 0.750 |
Why?
| | Proto-Oncogene Proteins c-akt | 9 | 2017 | 420 | 0.710 |
Why?
| | Signal Transduction | 16 | 2020 | 4713 | 0.650 |
Why?
| | ErbB Receptors | 4 | 2022 | 569 | 0.630 |
Why?
| | Mammary Neoplasms, Animal | 3 | 2015 | 29 | 0.620 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 5 | 2020 | 80 | 0.610 |
Why?
| | Mice, Nude | 11 | 2020 | 663 | 0.550 |
Why?
| | Transforming Growth Factor beta | 5 | 2023 | 462 | 0.550 |
Why?
| | Paracrine Communication | 1 | 2015 | 57 | 0.510 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 160 | 0.490 |
Why?
| | Protein Kinase Inhibitors | 3 | 2017 | 811 | 0.470 |
Why?
| | Phosphatidylinositol 3-Kinase | 2 | 2023 | 27 | 0.450 |
Why?
| | Tumor Microenvironment | 5 | 2022 | 454 | 0.440 |
Why?
| | Smad7 Protein | 4 | 2023 | 26 | 0.440 |
Why?
| | Mice | 24 | 2023 | 15528 | 0.410 |
Why?
| | Glucose Transporter Type 1 | 1 | 2011 | 42 | 0.400 |
Why?
| | Animals | 32 | 2023 | 33399 | 0.380 |
Why?
| | Stomatitis | 2 | 2021 | 14 | 0.370 |
Why?
| | Cell Proliferation | 8 | 2020 | 2275 | 0.370 |
Why?
| | Mucositis | 2 | 2021 | 20 | 0.370 |
Why?
| | Smad4 Protein | 2 | 2020 | 37 | 0.350 |
Why?
| | Apoptosis | 4 | 2020 | 2484 | 0.330 |
Why?
| | Mutation | 3 | 2015 | 3457 | 0.330 |
Why?
| | Fats | 1 | 2008 | 13 | 0.320 |
Why?
| | Mice, Transgenic | 10 | 2020 | 2025 | 0.320 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2017 | 671 | 0.310 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 336 | 0.310 |
Why?
| | Reactive Oxygen Species | 1 | 2009 | 576 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2020 | 740 | 0.290 |
Why?
| | Glucose | 2 | 2011 | 954 | 0.290 |
Why?
| | Wound Healing | 2 | 2018 | 270 | 0.280 |
Why?
| | rac1 GTP-Binding Protein | 2 | 2017 | 58 | 0.280 |
Why?
| | Keratinocytes | 3 | 2023 | 227 | 0.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1390 | 0.280 |
Why?
| | Disease Models, Animal | 7 | 2023 | 3730 | 0.270 |
Why?
| | Genes, p53 | 2 | 2020 | 64 | 0.270 |
Why?
| | Carcinogenesis | 2 | 2023 | 182 | 0.240 |
Why?
| | Phosphatidylinositols | 1 | 2023 | 52 | 0.230 |
Why?
| | Dermatitis | 1 | 2023 | 16 | 0.230 |
Why?
| | Receptors, Interleukin | 1 | 2023 | 41 | 0.230 |
Why?
| | Carcinogens | 1 | 2023 | 108 | 0.220 |
Why?
| | Humans | 34 | 2023 | 119032 | 0.220 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.220 |
Why?
| | Antineoplastic Agents | 4 | 2017 | 1974 | 0.220 |
Why?
| | Psoriasis | 1 | 2023 | 76 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 3 | 2017 | 59 | 0.220 |
Why?
| | Phosphorylation | 6 | 2015 | 1634 | 0.220 |
Why?
| | Glycerol | 1 | 2002 | 88 | 0.210 |
Why?
| | Laminin | 1 | 2022 | 68 | 0.210 |
Why?
| | Female | 25 | 2021 | 61588 | 0.210 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2022 | 63 | 0.210 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 158 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2018 | 1167 | 0.200 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2020 | 14 | 0.190 |
Why?
| | Keratin-15 | 1 | 2020 | 14 | 0.190 |
Why?
| | Radiation Injuries | 1 | 2021 | 131 | 0.190 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 52 | 0.190 |
Why?
| | Hyaluronan Receptors | 1 | 2020 | 93 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 144 | 0.180 |
Why?
| | Tumor Burden | 3 | 2018 | 275 | 0.170 |
Why?
| | Cell Movement | 3 | 2018 | 897 | 0.170 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 76 | 0.170 |
Why?
| | Receptor, EphB3 | 1 | 2018 | 4 | 0.170 |
Why?
| | Estradiol | 2 | 2013 | 476 | 0.160 |
Why?
| | Protein Binding | 2 | 2015 | 1975 | 0.160 |
Why?
| | Estrogen Receptor Modulators | 2 | 2017 | 19 | 0.160 |
Why?
| | Multiprotein Complexes | 2 | 2016 | 149 | 0.160 |
Why?
| | Lung Neoplasms | 3 | 2023 | 2220 | 0.160 |
Why?
| | Aminopyridines | 1 | 2018 | 85 | 0.160 |
Why?
| | Morpholines | 1 | 2018 | 106 | 0.150 |
Why?
| | Smokers | 1 | 2018 | 149 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.150 |
Why?
| | Immunoblotting | 2 | 2011 | 307 | 0.150 |
Why?
| | Disease-Free Survival | 2 | 2015 | 649 | 0.140 |
Why?
| | Extracellular Matrix | 2 | 2022 | 446 | 0.140 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 369 | 0.140 |
Why?
| | Estrogen Receptor alpha | 1 | 2017 | 126 | 0.140 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 245 | 0.140 |
Why?
| | Quinazolines | 2 | 2017 | 245 | 0.130 |
Why?
| | Hyperplasia | 2 | 2013 | 170 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2017 | 228 | 0.130 |
Why?
| | Amphiregulin | 1 | 2015 | 21 | 0.130 |
Why?
| | Down-Regulation | 2 | 2015 | 627 | 0.130 |
Why?
| | Protein Kinase C-alpha | 1 | 2015 | 43 | 0.130 |
Why?
| | Neuropeptides | 1 | 2015 | 68 | 0.130 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 968 | 0.130 |
Why?
| | Carrier Proteins | 2 | 2016 | 726 | 0.130 |
Why?
| | Cell Adhesion | 2 | 2022 | 443 | 0.130 |
Why?
| | Up-Regulation | 2 | 2015 | 872 | 0.130 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 137 | 0.130 |
Why?
| | Epidermal Growth Factor | 1 | 2015 | 173 | 0.130 |
Why?
| | Receptors, Estrogen | 1 | 2017 | 387 | 0.120 |
Why?
| | Quinolines | 1 | 2015 | 128 | 0.120 |
Why?
| | Morphogenesis | 1 | 2015 | 167 | 0.120 |
Why?
| | Transcriptome | 3 | 2018 | 756 | 0.120 |
Why?
| | Immunotherapy | 1 | 2018 | 493 | 0.120 |
Why?
| | Gene Expression | 3 | 2014 | 1492 | 0.120 |
Why?
| | Genes, erbB-2 | 1 | 2013 | 27 | 0.120 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 355 | 0.110 |
Why?
| | Receptors, Calcitriol | 2 | 2010 | 56 | 0.110 |
Why?
| | Heterografts | 3 | 2018 | 130 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 421 | 0.110 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2012 | 317 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2013 | 143 | 0.110 |
Why?
| | Mammary Tumor Virus, Mouse | 2 | 2011 | 41 | 0.110 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 3 | 2017 | 28 | 0.110 |
Why?
| | Pyrazoles | 1 | 2015 | 363 | 0.110 |
Why?
| | Macrophages | 1 | 2019 | 1324 | 0.110 |
Why?
| | Inflammation | 2 | 2023 | 2571 | 0.100 |
Why?
| | Autophagy | 1 | 2015 | 315 | 0.100 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1691 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 401 | 0.100 |
Why?
| | Gene Amplification | 3 | 2017 | 97 | 0.100 |
Why?
| | Cell Line | 3 | 2015 | 2707 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1774 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2013 | 164 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2018 | 762 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2017 | 1323 | 0.100 |
Why?
| | Mutation, Missense | 1 | 2013 | 300 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2023 | 1206 | 0.100 |
Why?
| | Alkylating Agents | 1 | 2010 | 25 | 0.100 |
Why?
| | Calcitriol | 1 | 2010 | 55 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 420 | 0.090 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 874 | 0.090 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1223 | 0.090 |
Why?
| | BRCA1 Protein | 1 | 2010 | 57 | 0.090 |
Why?
| | Prognosis | 4 | 2020 | 3443 | 0.090 |
Why?
| | Proteomics | 1 | 2015 | 876 | 0.090 |
Why?
| | Phthalazines | 2 | 2020 | 47 | 0.080 |
Why?
| | Cetuximab | 2 | 2020 | 99 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1012 | 0.080 |
Why?
| | Cell Death | 1 | 2009 | 339 | 0.080 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2008 | 112 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 287 | 0.080 |
Why?
| | Calcifediol | 1 | 2007 | 29 | 0.080 |
Why?
| | Vitamin D | 1 | 2010 | 354 | 0.080 |
Why?
| | Oxidative Phosphorylation | 1 | 2008 | 156 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1285 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1597 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2011 | 299 | 0.070 |
Why?
| | Piperazines | 2 | 2020 | 316 | 0.070 |
Why?
| | Models, Biological | 2 | 2018 | 1715 | 0.070 |
Why?
| | Carcinoma | 1 | 2008 | 204 | 0.070 |
Why?
| | Glycolysis | 1 | 2008 | 224 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 334 | 0.070 |
Why?
| | Skin | 2 | 2023 | 657 | 0.070 |
Why?
| | MAP Kinase Signaling System | 2 | 2011 | 293 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2008 | 828 | 0.070 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 356 | 0.070 |
Why?
| | Phenotype | 3 | 2023 | 3004 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2008 | 508 | 0.070 |
Why?
| | Cell Survival | 3 | 2015 | 1047 | 0.070 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 544 | 0.070 |
Why?
| | Blotting, Western | 3 | 2016 | 1195 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 4914 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 842 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2008 | 477 | 0.060 |
Why?
| | MCF-7 Cells | 2 | 2014 | 111 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 410 | 0.060 |
Why?
| | Nuclear Proteins | 1 | 2008 | 597 | 0.060 |
Why?
| | Phosphothreonine | 1 | 2002 | 6 | 0.060 |
Why?
| | Protein Phosphatase 2C | 1 | 2002 | 14 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2023 | 165 | 0.060 |
Why?
| | Osmosis | 1 | 2002 | 18 | 0.060 |
Why?
| | Glutathione Transferase | 1 | 2002 | 97 | 0.050 |
Why?
| | Protein Transport | 2 | 2017 | 412 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1059 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2023 | 128 | 0.050 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 565 | 0.050 |
Why?
| | Mitochondria | 1 | 2008 | 786 | 0.050 |
Why?
| | Catalytic Domain | 1 | 2002 | 206 | 0.050 |
Why?
| | Gene Products, tat | 1 | 2021 | 21 | 0.050 |
Why?
| | Plasmids | 1 | 2002 | 355 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2002 | 174 | 0.050 |
Why?
| | Disease Progression | 2 | 2020 | 2490 | 0.050 |
Why?
| | Green Fluorescent Proteins | 1 | 2002 | 395 | 0.050 |
Why?
| | Epithelium | 2 | 2012 | 305 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2002 | 412 | 0.050 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 25 | 0.050 |
Why?
| | Dogs | 1 | 2021 | 371 | 0.050 |
Why?
| | Feedback, Physiological | 1 | 2020 | 75 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 823 | 0.050 |
Why?
| | SOXB1 Transcription Factors | 1 | 2020 | 61 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2019 | 963 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 940 | 0.050 |
Why?
| | Transcription Factors | 1 | 2008 | 1570 | 0.040 |
Why?
| | Temperature | 1 | 2002 | 622 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 112 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 653 | 0.040 |
Why?
| | Clodronic Acid | 1 | 2019 | 9 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 5694 | 0.040 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2002 | 348 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2019 | 77 | 0.040 |
Why?
| | Kinetics | 1 | 2002 | 1625 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 151 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 1 | 2002 | 495 | 0.040 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 77 | 0.040 |
Why?
| | Radiation Injuries, Experimental | 1 | 2018 | 24 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 574 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 197 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 32 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 483 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 1947 | 0.040 |
Why?
| | Maytansine | 1 | 2017 | 13 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2023 | 893 | 0.040 |
Why?
| | rho Guanine Nucleotide Dissociation Inhibitor beta | 1 | 2017 | 4 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2017 | 32 | 0.040 |
Why?
| | DNA Repair | 1 | 2019 | 198 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 394 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 513 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2017 | 61 | 0.040 |
Why?
| | Trastuzumab | 1 | 2017 | 92 | 0.040 |
Why?
| | Cell Cycle | 2 | 2010 | 550 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2017 | 37 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 381 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 6414 | 0.040 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 52 | 0.040 |
Why?
| | RNA Interference | 1 | 2018 | 460 | 0.040 |
Why?
| | DNA Damage | 1 | 2018 | 357 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 175 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2015 | 4 | 0.030 |
Why?
| | Ligands | 1 | 2017 | 567 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2017 | 1096 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1167 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2015 | 149 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2015 | 57 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 3590 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 104 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2014 | 43 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2014 | 208 | 0.030 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 21 | 0.030 |
Why?
| | Cisplatin | 1 | 2015 | 271 | 0.030 |
Why?
| | Genes, myc | 1 | 2013 | 46 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 462 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2013 | 108 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2013 | 103 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 667 | 0.030 |
Why?
| | Gene Dosage | 1 | 2013 | 136 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2013 | 167 | 0.030 |
Why?
| | Drug Synergism | 1 | 2013 | 339 | 0.030 |
Why?
| | Phagocytosis | 1 | 2014 | 364 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2014 | 229 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2013 | 481 | 0.030 |
Why?
| | Postpartum Period | 1 | 2014 | 271 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9346 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 176 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 136 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2013 | 333 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2011 | 54 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2369 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 770 | 0.020 |
Why?
| | Alkylation | 1 | 2010 | 19 | 0.020 |
Why?
| | Cyclin A | 1 | 2010 | 15 | 0.020 |
Why?
| | Oligonucleotides, Antisense | 1 | 2011 | 100 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 618 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 195 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1267 | 0.020 |
Why?
| | Male | 4 | 2020 | 57818 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 59 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2010 | 161 | 0.020 |
Why?
| | Caspases | 1 | 2010 | 269 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2010 | 139 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 173 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 692 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.020 |
Why?
| | Estrogens | 1 | 2010 | 329 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 1900 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 681 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1308 | 0.020 |
Why?
| | Biological Transport | 1 | 2007 | 382 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2012 | 812 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2010 | 4081 | 0.010 |
Why?
| | Aged | 1 | 2018 | 19661 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 27627 | 0.010 |
Why?
|
|
Young's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|